J&J’s MonumenTAL-3 Data Rewrites the Myeloma Playbook Before the Ink Dries on DPd
MonumenTAL-3 delivers 81.3% PFS at 24 months for talquetamab plus daratumumab, threatening DPd's grip on earlier RRMM treatment lines.
No videos found.
Chiesi Presents Five Clinical Abstracts on Metreleptin at ENDO 2026
Chiesi presents five clinical abstracts on metreleptin at ENDO 2026, including Phase 3 trial data targeting label expansion in...
AbbVie’s Skyrizi Machine Is Writing Checks Its Oncology Pipeline Now Has to Cash
Skyrizi hit $4.48B in Q1 2026 revenue. AbbVie is deploying that cash into oncology—and the CLL14 nine-year data just...
Kromatid Names Matthew Hemstreet as Permanent CEO
Kromatid names Matthew Hemstreet as permanent CEO to accelerate KROMASURE platform adoption amid FDA guidance on genome editing safety...
Constantiam, Cincinnati Children’s Partner on Neuronopathic Gaucher Disease
Constantiam and Cincinnati Children's partner to develop genotype-matched therapies for neuronopathic Gaucher disease, addressing a genetic disorder with over...
Memento Medicines Raises $93M for Tie2/VEGF Bispecific Antibody in Retinal Disease
Memento Medicines raises $93M to develop MMT-205, a Tie2/VEGF bispecific antibody targeting retinal diseases nAMD and DME with clinical...
The $195 Million Voucher: How Denali Turned a Hunter Syndrome Approval Into a Pipeline War Chest
Denali's $195M PRV sale after AVLAYAH's March 2026 FDA approval reveals how rare disease wins now fund the next...
Biogen to Acquire RayThera for Up to $1 Billion
Biogen to Acquire RayThera for up to $1 billion, capturing a pre-clinical small-molecule immunology pipeline before Phase 1 dosing...
Biogen’s Immunology Buying Spree Reveals a Strategy the Neurology Playbook Can No Longer Support
Biogen's $1B RayThera deal is its second major immunology acquisition in two years. A pipeline pivot this deliberate signals...
Porosome Therapeutics Partners With India’s CSIR on Eight Disease Areas
Porosome Therapeutics Partners with India's CSIR to co-develop treatments across eight disease areas including Alzheimer's, cystic fibrosis, and COPD.